Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

Historic Finished Goods for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to $378636.0.

  • InMed Pharmaceuticals' Finished Goods fell 4391.94% to $378636.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $378636.0, marking a year-over-year decrease of 4391.94%. This contributed to the annual value of $676178.0 for FY2025, which is 1958.04% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Finished Goods of $378636.0 as of Q4 2025, which was down 4391.94% from $295809.0 recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Finished Goods high stood at $927182.0 for Q3 2024, and its period low was $231956.0 during Q1 2025.
  • Moreover, its 4-year median value for Finished Goods was $582161.0 (2022), whereas its average is $596273.0.
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 8873.19% in 2023, then crashed by 6809.59% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Finished Goods (Quarter) stood at $605956.0 in 2022, then fell by 7.94% to $557859.0 in 2023, then increased by 21.03% to $675164.0 in 2024, then crashed by 43.92% to $378636.0 in 2025.
  • Its Finished Goods was $378636.0 in Q4 2025, compared to $295809.0 in Q3 2025 and $676178.0 in Q2 2025.